Key insights
- Truist initiated coverage on Revolution Medicines with a buy rating and a $179 price target, citing the potential of its cancer drug daraxon, especially for pancreatic cancer. Upcoming data at the ASCO meeting could boost momentum. While recent earnings missed estimates due to higher expenses, the analyst's positive outlook and potential blockbuster drug status suggest a bullish, albeit speculative, outlook for the stock.
Investing.com - Truist Securities initiated coverage on Revolution Medicines Inc. (NASDAQ:RVMD) with a buy rating and set a price target of $179.00, up from a previous target of $116.00. The stock currently trades at $145.66, with shares up 268% over the past year. According to InvestingPro data, which tracks 1,400+ US equities with comprehensive analysis, the company trades near its 52-week high of $155.70 and carries a market capitalization of $31 billion.
The firm views daraxon as the leading candidate across RAS-mutant cancers, beginning with pancreatic ductal adenocarcinoma where it could capture more than 70% of the addressable market. Truist highlights Revolution’s first-in-class positioning, high efficacy barrier, and broad trial footprint as supporting a durable competitive advantage.
The analyst looks to upcoming data from the American Society of Clinical Oncology meeting to potentially reinforce the company’s momentum ahead of a likely near-term second-line pancreatic ductal adenocarcinoma approval. Truist also sees upside from a faster path to first-line treatment.
Daraxon’s potential emergence as a blockbuster drug, alongside zoldon and eliron as follow-on candidates, form the core pillars of the firm’s investment thesis. Analyst Gregory Renza assumes coverage on the stock.
Revolution Medicines focuses on developing targeted oncology therapies for patients with RAS-mutant cancers.
In other recent news, Revolution Medicines Inc. reported its first-quarter 2026 earnings, revealing a loss per share of negative $2.29, which fell short of the consensus estimate of negative $1.64. The shortfall was attributed to higher-than-expected selling, general, and administrative expenses, alongside research and development costs that exceeded projections. Despite these financial challenges, the company highlighted a strong cash position during its earnings call, emphasizing strategic advancements in its clinical pipeline.
Additionally, Revolution Medicines announced that data from its Phase 1/2 trial evaluating daraxonrasib for metastatic RAS mutant pancreatic ductal adenocarcinoma was published in The New England Journal of Medicine. This follows previously announced positive topline results from its Phase 3 RASolute 302 trial. Meanwhile, Needham adjusted its price target for Revolution Medicines to $183, down from $186, while maintaining a Buy rating, citing increased costs as a factor. These developments reflect the company’s ongoing efforts and challenges in its clinical and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.